MedTrace Logo

Miltefosine for Brazilian Visceral Leishmaniasis

NCT00378495 · Status: TERMINATED · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 80

Last updated 2016-07-12

No results posted yet for this study

Summary

Miltefosine will be administered to Brazilian patients with kala azar

Conditions

  • Kala Azar

Interventions

DRUG

Miltefosine: initially 2.5 mg/kg/day for 28 days

Sponsors & Collaborators

  • AEterna Zentaris

    collaborator INDUSTRY

  • AB Foundation

    lead OTHER

Principal Investigators

  • Reynaldo Dietze · Núcleo de Doenças Infecciosas - UFES

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
2 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2005-04-30
Primary Completion
2007-04-30
Completion
2007-10-31

Countries

  • Brazil

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00378495 on ClinicalTrials.gov